Influenza Vaccine (split Virion), inactivated

Influenza Vaccine (split Virion), inactivated Product Description

1. Vaccine Composition

The split virion inactivated vaccine contains fragmented components of the influenza virus. Instead of using whole, intact viruses, the virus particles are chemically or mechanically disrupted into smaller pieces. These fragments, mainly the surface antigens like hemagglutinin (HA) and neuraminidase (NA), are what trigger the immune response in the body. By presenting these key antigenic parts, the vaccine effectively teaches the immune system to recognize and combat the actual influenza virus. The inactivation process ensures that the virus is no longer capable of causing infection while retaining its immunogenicity. This is achieved through methods such as treatment with formaldehyde or other appropriate agents, rendering the virus harmless but still antigenically active.

2. Production Methodology

The production of Influenza Vaccine (split Virion), inactivated begins with the selection of the appropriate influenza virus strains. As with other influenza vaccines, this is based on the global surveillance and predictions made by organizations like the WHO. Once the strains are determined, they are cultivated in a suitable host system. Commonly, fertilized chicken eggs are used, although cell culture-based methods are also emerging as viable alternatives. The viruses are allowed to replicate and then harvested. Subsequently, the purification process takes place to isolate the virus particles. The splitting of the virions into fragments is a carefully controlled step, ensuring the right size and antigenic integrity of the pieces. After splitting, the inactivation step is carried out, followed by formulation with adjuvants in some cases. Adjuvants can enhance the immune response, potentially reducing the amount of antigen needed per dose and improving the overall efficacy of the vaccine.